AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, ...

The Cambridge-based pharmaceuticals maker has agreed to pay up to USD1 billion for EsoBiotec SA on a cash and debt free basis. This includes an initial payment of USD425 million on deal closing, and ...

Lawmakers on th Senate Health Committee advanced a bill Tuesday that, if made law, will allow pharmacists in the state to ...

Carlsbad: Ionis Pharma and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment ...